Future Tech

The Future Tech Pavilion (FUTEX), co-organized by NSTC, Academia Sinica, MOE, and MOHW, themed as "Global Tech and Industry tie with Taiwan", gathering cutting-edge research achievements from all over the world.

Home

Future Tech

Recommended Technology

Vesicles comprising lectins expressed on the surface and methods of use thereof to deliver an agent to autophagic and apoptotic cells

This technology is an in vivo tissue-specific drug delivery system using tar geted liposomes. It provides the following advantages: (1) Reduced toxicit y, improved stability and solubility, prolonged circulation, increased drug concentration in inflamed or tumor tissues, and enhanced safety. (2) Integ ration of cell-recognition ligands on the carrier surface enables precise dr ug release to target cells. This liposome delivers drugs to autophagic and apoptotic cells and associated tissues, resulting in synergistic effects and i mproved efficiency. Advantages include: (1) Pioneering and efficient in viv o drug targeting system for damaged tissues without external guidance. (2) Reduced side effects and dosage through precise targeting. (3) Innovat ive drug platform for damaged tissues. Precise targeting in drug delivery is trending, but limited in vivo applicabil ity due to multifactorial diseases and drug resistance. A multi-target syste m covering various tissues is urgently needed. Liposomal drug delivery is mature with clinical trials, but multiple factors in cancer and chronic disea ses require multiple injections and lead to resistance. To overcome this lim itation, our team has focused on research and development. After extensi ve efforts, we have successfully developed an innovative drug delivery car rier with the following advantages:(1) It encapsulates diverse drugs (hydrophobic, hydrophilic, DNA, siRNA) f or multiple indications. (2) The targeting molecules possess multi-targeting capabilities (autopha gic and apoptotic cells) and additional functions like anti-inflammatory an d anti-hypoxia effects. (3) It can be customized with single-target or synergistic-targeting molec ules for different disease types. (4) It can be combined with immune checkpoint inhibitors or other biologi c therapies to optimize treatment strategies.

Future Tech | Biotechnology & Medical care

Event Gallery

Coming soon!

TOP

Login

Account

Password